Cargando…

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

OBJECTIVES: The aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with moderate-to-severe disease activity who had previously failed tumour necrosis factor (TNF) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genovese, Mark C, Fleischmann, Roy, Furst, Daniel, Janssen, Namieta, Carter, John, Dasgupta, Bhaskar, Bryson, Judy, Duncan, Benjamin, Zhu, Wei, Pitzalis, Costantino, Durez, Patrick, Kretsos, Kosmas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/ https://www.ncbi.nlm.nih.gov/pubmed/24641941 http://dx.doi.org/10.1136/annrheumdis-2013-204760

Ejemplares similares

Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
por: Genovese, Mark C., et al.
Publicado: (2021)

Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab
por: Kretsos, K, et al.
Publicado: (2014)

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
por: Nasonov, Evgeniy, et al.
Publicado: (2022)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment
por: Bure, Irina V., et al.
Publicado: (2020)

Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2022)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients
por: Nerviani, Alessandra, et al.
Publicado: (2020)

The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis
por: Abuelazm, Mohamed, et al.
Publicado: (2023)

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
por: Humby, Frances, et al.
Publicado: (2021)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
por: Shaw, Stevan, et al.
Publicado: (2014)

Higher expression of TNFα-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy
por: De Groof, Aurélie, et al.
Publicado: (2016)

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
por: Huizinga, Tom W J, et al.
Publicado: (2014)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Leveraging systems biology approaches in clinical pharmacology
por: Melas, Ioannis N, et al.
Publicado: (2013)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers—A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania
por: Faini, Diana, et al.
Publicado: (2022)

Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
por: Genovese, Mark C., et al.
Publicado: (2016)

Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series
por: ten Hagen, Alexander, et al.
Publicado: (2022)

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study
por: Combe, Bernard, et al.
Publicado: (2014)

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
por: Smolen, Josef S, et al.
Publicado: (2017)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

The inadequate corpus luteum
por: Duncan, W Colin
Publicado: (2021)

Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter
por: Whitehead, Maria A., et al.
Publicado: (2012)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
por: Genovese, Mark C, et al.
Publicado: (2018)

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
por: Emery, P, et al.
Publicado: (2010)

Defining predatory journals and responding to the threat they pose: a modified Delphi consensus process
por: Cukier, Samantha, et al.
Publicado: (2020)

Geographic and socioeconomic differences in heat-related mortality among the Dutch population: a time series analysis
por: de Visser, Mara, et al.
Publicado: (2022)

Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol
por: Dossing, Anna, et al.
Publicado: (2014)

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial
por: Zimmer, Robert, et al.
Publicado: (2013)

Phosphate reabsorption in the kidney: NaPi-IIb or not IIb
por: Burns, David, et al.
Publicado: (2020)

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
por: Perez-Ruiz, Fernando, et al.
Publicado: (2016)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Neighbourhood walkability, daily steps and utilitarian walking in Canadian adults
por: Hajna, Samantha, et al.
Publicado: (2015)

Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome
por: Newton, Julia L, et al.
Publicado: (2012)

Parental encouragement is positively associated with outdoor active play outside of school hours among 7–12 year olds
por: Ferrao, Thomas, et al.
Publicado: (2015)

Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study
por: D'Agostino, Maria-Antonietta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8uhv9cpssp051tnealg3bth1af